Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 8/20 | 0.60 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.55 |
| ▸ | F13A1 | P00488 | 1/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omiganan SCHEMBL27824120 | 0.92 | CXCR4 (0.60) | CXCR4NTSR2NTSR1SORT1CAPN1 | |
| Omiganan SCHEMBL29410943 | 0.91 | CXCR4 (0.59) | CXCR4NTSR2NTSR1SORT1CAPN1 | |
| SCHEMBL28202049 | 0.91 | CXCR4 (0.60) | CXCR4NTSR2NTSR1SORT1CAPN1 | |
| SCHEMBL29675079 | 0.91 | CXCR4 (0.60) | CXCR4NTSR2NTSR1SORT1CAPN1 | |
| SCHEMBL30343340 | 0.90 | C5AR1 (0.60) | CXCR4NTSR2NTSR1SORT1KEAP1 | |
| SCHEMBL29412263 | 0.89 | CXCR4 (0.61) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL30864786 | 0.89 | C5AR1 (0.59) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL30273393 | 0.89 | CXCR4 (0.61) | CXCR4NTSR2NTSR1SORT1KISS1R | |
| SCHEMBL29674929 | 0.88 | CXCR4 (0.59) | CXCR4KISS1R | |
| SCHEMBL31208374 | 0.88 | C5AR1 (0.58) | CXCR4NTSR2NTSR1SORT1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139313-A1 | SAFE SEQUENCING SYSTEM | THE JOHNS HOPKINS UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| US-12539510-B2 | Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge | CEPHEID (US) | 2026-02-03 | — | — | US | disclosed |
| US-12534759-B2 | Safe sequencing system | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250215508-A1 | CRISPR-Cas9 AS A SELECTIVE AND SPECIFIC CELL KILLING TOOL | THE JOHNS HOPKINS UNIVERSITY | 2025-07-03 | — | — | US | disclosed |
| WO-2025108481-A1 | METHOD FOR RAPIDLY DETECTING MYCOBACTERIUM TUBERCULOSIS | 上海科技大学 | 2025-05-30 | — | — | WO | disclosed |
| US-20250171847-A1 | SAFE SEQUENCING SYSTEM | JPMORGAN CHASE BANK, N.A. | 2025-05-29 | — | — | US | disclosed |
| CN-120041587-A | Method for rapid detection of mycobacteria | 上海科技大学 | 2025-05-27 | — | — | CN | disclosed |
| US-12252743-B2 | Safe sequencing system | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-03-18 | — | — | US | disclosed |
| US-12209281-B2 | Safe sequencing system | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| CN-119286759-A | Aloe exosome-like nano vesicle capable of delaying skin photoaging and extraction method and application thereof | 江苏大学 | 2025-01-10 | — | — | CN | disclosed |
| US-11773440-B2 | Safe sequencing system | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| CN-113527460-B | Arac mutant AraCmt1 for sensing explosive molecules, screening method and application thereof | 青岛农业大学 | 2023-06-20 | — | — | CN | disclosed |
| US-20230101335-A1 | EX VIVO TISSUE EXPLANT AND GRAFT PLATFORM AND USES THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2023-03-30 | — | — | US | disclosed |
| US-11603555-B2 | Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or MRNA expression levels in an automated reaction cartridge | CEPHEID (US) | 2023-03-14 | — | — | US | disclosed |
| US-20220316005-A1 | SAFE SEQUENCING SYSTEM | THE JOHNS HOPKINS UNIVERSITY | 2022-10-06 | — | — | US | disclosed |
| US-11459611-B2 | Safe sequencing system | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-10-04 | — | — | US | disclosed |
| US-11453913-B2 | Safe sequencing system | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220226809-A1 | INTEGRATED PURIFICATION AND MEASUREMENT OF DNA METHYLATION AND CO-MEASUREMENT OF MUTATIONS AND/OR MRNA EXPRESSION LEVELS IN AN AUTOMATED REACTION CARTRIDGE | CEPHEID (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220119788-A1 | PROGRAMMABLE NUCLEASE IMPROVEMENTS AND COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATION AND DETECTION | MAMMOTH BIOSCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
| CN-111434693-B | Antioxidant fusion protein and application thereof | 江苏芝大生物科技有限公司 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539510-B2 | Integrated purification and measurement of DNA methylation and co-measurement of mutations and/or mRNA expression levels in an automated reaction cartridge | DNMT3A, DNMT1, NSUN2 | CXCR4 2503/4885NTSR2 4719/4885NTSR1 4625/4885 |
| US-12534759-B2 | Safe sequencing system | POLRMT, SSBP1, IARS2 | CXCR4 4412/4885NTSR2 3369/4885NTSR1 3126/4885 |
| US-20260139313-A1 | SAFE SEQUENCING SYSTEM | FARS2, POLRMT, TFAM | CXCR4 4263/4885NTSR2 4053/4885NTSR1 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.